5 papers in the library · 167 citations · publishing 2023-2024
BMJ November 19, 2024 Cédric Lemarchand, Raphaël Chopin, M Paul et al. 9 citations
Cédric Lemarchand and colleagues highlight weaknesses in the evidence on efficacy and safety of hallucinogens and question the use of expedited regulatory pathways
JAMA Psychiatry April 10, 2024 Eiko I. Fried, Ioana A. Cristea, Florian Naudet 2 citations
To the Editor According to the study protocol, the recently published study by Aaronson et al1 was carried out “to assess effectiveness of 25 mg of psilocybin in [15] patients with treatment-resistant type 2 bipolar depression.” We see 3 concerns.
March 10, 2023 Michiel van Elk, Eiko I. Fried 30 citations preprint
Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders. This optimism is reflected in a considerable increase in research papers, investments by pharmaceutical companies, patents, media coverage, as well as political and legislative changes. However, psychedelic science is facing serious challenges that...
Therapeutic Advances in Psychopharmacology 2023 Michiel van Elk, Eiko I. Fried 126 citations
Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders. This optimism is reflected in an increase in research papers, investments by pharmaceutical companies, patents, media coverage, as well as political and legislative changes. However, psychedelic science is facing serious challenges that threaten the...
Eiko I. Fried preprint
This is a commentary on a recent editorial in Current Psychiatry in with the editor makes a number of incorrect assertions regarding the default mode network and mental health in youth. The present commentary corrects these false claims.